BREAKING NEWS
Cloud Server Hosting For Online Businesses
Inexpensive SEO Services
Benefits of Wanting to play Free Online Slot machines
MRNA-5671

Summary

mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna.[1] It is a tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the KRAS gene.[2] It is currently being evaluated for the treatment of either non-small cell lung cancer, colorectal cancers with microsatellite instability, or pancreatic adenocarcinoma, all with confirmed KRAS driver mutations.[3]

mRNA-5671
Vaccine description
TargetCancer driven by G12D, G12V, G13D or G12C mutation in the KRAS gene
Vaccine typemRNA
Clinical data
Routes of
administration		Intramuscular
ATC code

References edit

  1. ^ "mRNA 5671". AdisInsight. Springer Nature Switzerland AG.
  2. ^ "mRNA-derived KRAS-targeted vaccine V941". National Cancer Institute Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services.
  3. ^ Clinical trial number NCT03948763 for "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)" at ClinicalTrials.gov